Ampliphi Biosciences Corp (NYSEAMERICAN:APHB – Get Free Report) was up 1.1% during trading on Thursday . The company traded as high as $1.99 and last traded at $1.97. Approximately 5,721 shares traded hands during mid-day trading, a decline of 99% from the average daily volume of 842,200 shares. The stock had previously closed at $1.95.
Ampliphi Biosciences Stock Performance
About Ampliphi Biosciences
AmpliPhi Biosciences Corporation, a biotechnology company, focuses on the development of therapies for antibiotic-resistant infections using bacteriophage-based technology. The company is involved in developing AB-SA01 for the treatment of staphylococcus aureus (S. aureus) infections; and AB-PA01 for the treatment of pseudomonas aeruginosa (P.
Read More
- Five stocks we like better than Ampliphi Biosciences
- Procter & Gamble (NYSE:PG) Pulls Back After Shaky Guidance
- MercadoLibre: Latin America’s Digital Titan Just Got Cheaper
- The Significance of a Trillion-Dollar Market Cap Goes Beyond a Number
- Breaking Down Pegasystems, A Wedbush Top AI Pick for 2025
- Bank Stocks – Best Bank Stocks to Invest In
- Shutterstock and Getty: A $3.7 Billion Visual Content Giant
Receive News & Ratings for Ampliphi Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ampliphi Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
